Procter & Gamble (P&G) has agreed to acquire Thorne, a maker of premium vitamins and supplements, for $3.8 billion. The deal, announced Tuesday, marks the consumer-goods giant's latest push into the fast-growing self-care market, where multinationals are increasingly competing for shelf space.
P&G CEO Shailesh Jejurikar told CNBC the purchase price is in line with industry benchmarks, according to Reuters. The acquisition will add Thorne to P&G's existing supplements portfolio, which already includes New Chapter, Metamucil, and Align.
Why P&G is buying Thorne
Thorne is known for its science-backed supplements, often used by health professionals and athletes. The brand fits neatly into P&G's beauty and wellness division, which has been a bright spot for the company. Even as P&G expects slower overall sales growth, shoppers have continued to spend on discretionary self-care products like vitamins and wellness items.
The deal reflects a broader trend: large consumer companies are snapping up smaller wellness brands to capture demand from health-conscious consumers. Supplements are seen as a resilient category because they appeal to people looking to manage their health proactively, even during economic uncertainty.
For P&G, the acquisition is a way to deepen its presence in a market that is growing faster than traditional household goods. It also gives the company access to Thorne's direct-to-consumer channel and its loyal customer base, which could help P&G build stronger relationships with shoppers.
What it means for investors
For everyday investors, this deal is a reminder that big consumer companies are willing to pay up for growth in wellness. P&G's move suggests it sees supplements as a key area for future expansion, even as its core business faces headwinds from slower demand and rising costs.
Investors should note that P&G is paying a significant premium for Thorne, which could weigh on short-term earnings. However, the company's management believes the acquisition will pay off over the long run by boosting sales in a high-margin category.
The deal also highlights the competitive landscape in self-care. Other consumer giants, including Nestlé and Unilever, have made similar acquisitions in recent years. This consolidation could lead to higher prices for consumers, but it also signals confidence in the long-term growth of the wellness industry.
For those holding P&G stock, the key question is whether the company can successfully integrate Thorne and deliver the expected synergies. P&G has a track record of integrating brands well, but supplements are a different beast from diapers or detergent. Investors will be watching to see if Thorne's growth continues under P&G's ownership.
In the broader market, this deal is part of a wave of M&A activity. Just this week, warehouse giant Prologis agreed to buy UK rival Segro for £14.3 billion, showing that companies are still willing to make big bets despite economic uncertainty.
For consumers, the acquisition likely means more Thorne products will appear in mainstream retail outlets, potentially at lower prices as P&G leverages its distribution network. But it could also lead to fewer choices if competitors respond with their own deals.
Looking ahead
The deal is expected to close later this year, pending regulatory approval. P&G has not said whether it will keep Thorne's management team or make changes to its product lineup. Investors will get more details when the company reports its next quarterly earnings.
In the meantime, the acquisition underscores a key theme for 2025: consumer companies are betting that health and wellness will remain a priority for shoppers, even as they cut back on other discretionary spending. Whether that bet pays off will depend on how well P&G can turn Thorne into a household name.
